NASDAQ:APRE

Aprea Therapeutics Q4 2024 Earnings Results & Report

Aprea Therapeutics logo
$0.45 +0.05 (+11.52%)
Closing price 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.46%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics beat analyst expectations on both earnings and revenue in its Q4 2024 results, released March 25, 2025. The company reported EPS of -$0.49 versus the -$0.69 consensus estimate, while revenue of $206 thousand topped the $150 thousand estimate by $56.00 thousand.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Aprea Therapeutics EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.69
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Aprea Therapeutics Revenue Results

Actual Revenue
$206 thousand
Expected Revenue
$150 thousand
Beat/Miss
Beat by +$56.00 thousand
YoY Revenue Growth
N/A

Aprea Therapeutics Q4 2024 Earnings FAQ

Aprea Therapeutics (NASDAQ:APRE) reported earnings of -$0.49 per share for Q4 2024, beating the consensus estimate of -$0.69. The report was announced on Tuesday, March 25, 2025.

Aprea Therapeutics reported revenue of $206 thousand for Q4 2024, against a consensus estimate of $150 thousand.

Aprea Therapeutics Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a clinical-stage biotechnology company focused on developing investigational cancer treatments. Its research centers on the DNA damage response, a network of cellular processes that helps repair damaged DNA and that can be targeted in some cancers.

The company’s pipeline has included ATR inhibitors, a class of experimental medicines intended to disrupt cancer cells’ ability to respond to DNA damage. Aprea has evaluated these candidates in early-stage clinical research; they are investigational and have not been established as approved treatments.

View Aprea Therapeutics Profile